

Long-Term Safety and Clinical Outcomes of LivMarli in Patients in the United States (LEAP-US)

NCT06193928

Status RECRUITING
Sponsor Mirum Pharmaceuticals, Inc.
Enrollment 70 participants

Key Eligibility Criteria

Inclusion (2)

- A clinically and/or genetically confirmed ALGS diagnosis or PFIC diagnosis
- Participant prescribed Livmarli

Exclusion (5)

- Refusal to provide informed consent/assent (if required by the local IRB)
- Previously or currently on Livmarli through participation in a clinical study or expanded access program
- Participants who have previously received an SBD or LT
- Any condition or abnormalities that, in the opinion of the investigator, may interfere with the participant participating in or completing the study
- Participants who have received an investigational drug within 30 days of the first dose of Livmarli

Locations (8 total)

Children's Hospital Los Angeles CHLA, Los Angeles, California, United States
Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado, Aurora, Colorado, United States
Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta, Georgia, United States
... and 5 more locations

<https://clinicaltrials.gov/study/NCT06193928>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).